Septerna, Inc. Common Stock (SEPN) Stock
Fundamentals
Recent news

Septerna, Inc. (SEPN) Reports Q2 Loss, Beats Revenue Estimates
Septerna, Inc. (SEPN) Reports Q2 Loss, Beats Revenue Estimates
SEPN

Septerna's Chief People Officer Sold Nearly 12,000 Company Shares. What Does That Mean for Investors?
Septerna's Chief People Officer Sold Nearly 12,000 Company Shares. What Does That Mean for Investors?
SEPN

Is Septerna a Stock to Sell After an Insider Let Go of 15,000 Shares?
Is Septerna a Stock to Sell After an Insider Let Go of 15,000 Shares?
SEPN

Analysts Think These Stocks Could More Than Double in Value
Analysts Think These Stocks Could More Than Double in Value
SEPN
Technical indicators
- RSI 14
- 37.89
- MACD 12/26/9
- -0.39
- EMA 9 of MACD
- -0.14
- MACD histogram
- -0.25
- SMA 50
- $39.22
- Price below SMA 50
- EMA 50
- $38.01
- Price below EMA 50
- SMA 200
- $30.98
- Price above SMA 200
- EMA 200
- $31.80
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of October 6, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 5 analysts
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
No data available
Debt & Balance Sheet
No data available
Revenue to Profit
No data available
Earnings
No data available
Latest news

Septerna, Inc. (SEPN) Reports Q2 Loss, Beats Revenue Estimates
Septerna, Inc. (SEPN) Reports Q2 Loss, Beats Revenue Estimates
SEPN

Septerna's Chief People Officer Sold Nearly 12,000 Company Shares. What Does That Mean for Investors?
Septerna's Chief People Officer Sold Nearly 12,000 Company Shares. What Does That Mean for Investors?
SEPN

Is Septerna a Stock to Sell After an Insider Let Go of 15,000 Shares?
Is Septerna a Stock to Sell After an Insider Let Go of 15,000 Shares?
SEPN

Analysts Think These Stocks Could More Than Double in Value
Analysts Think These Stocks Could More Than Double in Value
SEPN

ETFs to Capitalize on the Novo Nordisk-Septerna Deal
ETFs to Capitalize on the Novo Nordisk-Septerna Deal
SEPN

Septerna Stock Surges on Oral Obesity Drug Deal With Novo Nordisk
Septerna Stock Surges on Oral Obesity Drug Deal With Novo Nordisk
SEPN

Septerna stock pops on partnership with Novo Nordisk to develop obesity therapies
Septerna stock pops on partnership with Novo Nordisk to develop obesity therapies
SEPN

Novo Nordisk Inks A Major Obesity Deal, Sending Shares Of New Partner Septerna Skyrocketing
Novo Nordisk Inks A Major Obesity Deal, Sending Shares Of New Partner Septerna Skyrocketing
SEPN

Novo Nordisk strikes $2.2 billion deal with Septerna to develop new obesity treatments
Novo Nordisk strikes $2.2 billion deal with Septerna to develop new obesity treatments
SEPN

Insiders Are Loading Up on These 6 Stocks Now
Insiders Are Loading Up on These 6 Stocks Now
SEPN
About Septerna, Inc. Common Stock
Septerna Inc is a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by a proprietary Native Complex Platform. Its industrial-scale platform aims to unlock the full potential of GPCR therapies. The group discovery and development of a pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic disease. Its pipeline includes SEP-786 (PTH1R), SEP-631 (MRGPRX2), TSHR, GLP-1R, GIPR, and GCGR.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Jeffrey T. Finer M.D., Ph.D. | Co-Founder, CEO & Director | 1967 |
| Ms. Elizabeth P. Bhatt M.B.A., M.S. | President & COO | 1968 |
| Mr. Gilbert M. Labrucherie C.F.A., J.D. | Chief Financial Officer | 1972 |
| Dr. Robert J. Lefkowitz M.D. | Co-Founder and Member of Cross-Functional Scientific & Drug Discovery Advisory Board | 1944 |
| Dr. Arthur Christopoulos BPHARM, Ph.D. | Co-Founder and Member of Cross-Functional Scientific & Drug Discovery Advisory Board | — |
| Dr. Patrick Sexton Ph.D. | Co-Founder and Member of Cross-Functional Scientific & Drug Discovery Advisory Board | — |
| Mr. Richard Hansen Ph.D. | Vice President of Technology | — |
| Mr. Mark A. Wilson J.D. | Chief Legal Officer | 1972 |
| Mr. George Xu Ph.D. | Senior Director of Corporate Development & Portfolio Strategy | — |
| Ms. Samira Shaikhly | Chief People Officer | 1970 |
Fundamentals
Valuation
Earnings Per Share
Income Statement
Dividend
Technical indicators
- RSI 14
- 37.89
- MACD 12/26/9
- -0.39
- EMA 9 of MACD
- -0.14
- MACD histogram
- -0.25
- SMA 50
- $39.22
- Price below SMA 50
- EMA 50
- $38.01
- Price below EMA 50
- SMA 200
- $30.98
- Price above SMA 200
- EMA 200
- $31.80
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of October 6, 2026. Technical data, not a recommendation.
Analyst views
5 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $48.00
- Average
- $54.20
- High
- $62.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +0.0 | -0.5 | +9.1 | +3.8 | -0.5 |



